The present invention relates to a process for the preparation of biodegradable microcapsules, in particular biodegradable protein- and/or polysaccharide-based microcapsules, as well as dispersions of such microcapsules (microcapsule slurry) that enclose at least one hydrophobic active ingredient. In addition, the present invention relates to biodegradable microcapsules obtainable by the process according to the invention. In another aspect, the present invention relates to the use of the microcapsules and dispersions as an ingredient in consumer products.

Softgel capsules have a fill composition that administers a 200 to 500 mg dose of magnesium from magnesium oxide and an outer sofgel gelatin shell. The composition includes 55 to 70% w/w of an edible oil, 2 to 8% w/w polysorbate 80, 0.5 to 2% w/w hydrophobic silica, and 0.2 to 4% w/w of a chelating agent for binding to magnesium. The softgel capsules have a dissolution according to USP <711> of greater than NLT 75% (Q).

A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.

The present invention relates to methods for regenerating nervous system tissue or treating a neurological disorder by administration of a therapeutically effective amount of synthetic tissue containing a cell population of one or more nervous system cell types (e.g., neurons) or multipotent cells (e.g., mesenchymal stem cells), where the cell population is embedded within a modular synthetic hydrogel that is biocompatible. In some preferred embodiments the modular synthetic hydrogel includes a PEG hydrogel crosslinked with a glycosaminoglycan such as hyaluronan.

The present invention relates to a gelatin product comprising a core component, wherein the core component is encased partially or fully by a gelatin gel. The gelatin gel is produced from a homogeneous casting compound containing the following constituents dissolved in water: 3 to 20 wt % of gelatin having a mean molecular weight, determined by gel chromatography, of at least 130 kDa, wherein the proportion of the molecular weight fraction above 100 kDa is at least 35 wt %; up to 60 wt % of glucose syrup with a viscosity of less than 1000 mPa.Math.s, measured with a dry matter content of 80 wt % and at a temperature of 60° C.; and up to 60 wt % of sucrose,
wherein the casting compound comprises a dry matter content of at least 70 wt %.

A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.

Particles for delivery of therapeutic agents are disclosed. In one embodiment, a particle for delivery of a therapeutic agent includes a hydrogel polymer matrix, a plurality of hydrophobic encapsulation sites within the hydrogel polymer matrix, and a hydrophobic therapeutic agent encapsulated within at least some of the encapsulation sites. The hydrogel polymer matrix may be hydrophilic. The hydrophobic encapsulation sites may comprise cyclodextrin conjugated to the hydrogel polymer matrix. The hydrogel polymer matrix comprises gelatin. The particle may have a diameter of 10 nm to 50 μm.

An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI.sub.2) or acid dissociation constant (pKa.sub.2) that is greater than the isoelectric point (pI.sub.1) or acid dissociation constant (pKa.sub.1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, α-protio, α-deutero-N,N-dimethyltryptamine compounds, α,α-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I):

##STR00001## wherein: the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R.sup.1 is independently selected from H and D; R.sup.2 is selected from CH.sub.3 and CD.sub.3; R.sup.3 is selected from CH.sub.3 and CD.sub.3; each .sup.yH is independently selected from H and D, or a pharmaceutically acceptable salt thereof.

Provided herein are compositions and methods of use thereof for the treatment of fungal infections and diseases.